News

News

Pictured: A Kras/Lkb1 tumour that has been graphically distorted to capture each cell separately. Researchers have found some cancer and T cells rely on the same energy sources in the complex tumour microenvironment of lung cancer. Credit: WEHI

Melbourne researchers have discovered cancer and immune cells rely on the same energy sources from our body to thrive which could trigger a fundamental rethink of treatment options for some lung cancer patients. 

30 June 2022
 A healthy human T cell. Re-eingineered T cells are put back into a patient during CAR T cell therapy.   Credit: National Cancer Institute (NCI)

Researchers have developed a way to potentially reduce the toxic side-effects of a type of immunotherapy, in findings that could overcome the pioneering treatment’s biggest limitation.

21 June 2022
Professor Clare Scott AM

WEHI researcher and clinician Professor Clare Scott has been recognised in the 2022 Queen’s Birthday Honours List, with one of Australia’s highest civilian honours. 

13 June 2022
Researchers from successful round 5 applications

The National Drug Discovery Centre is pleased to announce the selection of four projects that will now receive generous Australian Government subsidies to support high-throughput screening campaigns.

8 June 2022
Tumor DNA fragment by Drew Berry, wehi.tv

Researchers have developed a new blood test that could revolutionise how chemotherapy is used for colon cancer, by identifying the patients that need chemo and those that can be safely spared treatment.

8 June 2022
Corey Tutt

WEHI has partnered with leading Indigenous not-for-profit, DeadlyScience, to foster the next generation of Aboriginal and Torres Strait Islander scientists, in the first partnership of its kind.

27 May 2022
Researchers hope the findings could help reduce the industry’s high drug failure rate.

Researchers have boosted pioneering technology to show whether potential treatments are worth progressing into human trials, in a game-changing move that could dramatically reduce the high failure rates in drug discovery and development. 

24 May 2022
‘A 3D surface representation showing the inhibitor WM382 (in green) bound within the active site cleft of the pacman’s mouth, the plasmepsinX ( in grey). This event blocks the ability of plasmepsinX to process other parasite proteins required for the entry and exit of red blood cells.

Revolutionary 3D images have enabled researchers to understand how new anti-malaria compounds kill malaria parasites, paving the way for the next generation anti-malarial treatments. 

16 May 2022
Dr Paola Favuzza will spend a year at MMV in Switzerland as part of the fellowship

WEHI’s Dr Paola Favuzza has received an MTPConnect Researcher Exchange and Development within Industry (REDI) fellowship, that will provide her with the vital industry experience required to turn basic scientific research into positive outcomes for patients. 

13 May 2022
Antibodies binding the SARS-CoV-2 virus. This research could help reduce the severity of viruses like COVID-19 in the future

A WEHI-led study has identified a new enzyme involved in controlling cell death, in findings that could lead to better treatment options for a range of inflammatory conditions, cancers and viruses.

12 May 2022

Pages